Abstract

BackgroundAlzheimer disease (AD) and other types of dementia are now considered one of the world’s most pressing health problems for aging people worldwide. It was the seventh-leading cause of death, globally, in 2019. With a growing number of patients with dementia and increasing costs for treatment and care, early detection of the disease at the stage of mild cognitive impairment (MCI) will prevent the rapid progression of dementia. In addition to reducing the physical and psychological stress of patients’ caregivers in the long term, it will also improve the everyday quality of life of patients.ObjectiveThe aim of this study was to design a digital screening system to discriminate between patients with MCI and AD and healthy controls (HCs), based on the Rey-Osterrieth Complex Figure (ROCF) neuropsychological test.MethodsThe study took place at National Taiwan University between 2018 and 2019. In order to develop the system, pretraining was performed using, and features were extracted from, an open sketch data set using a data-driven deep learning approach through a convolutional neural network. Later, the learned features were transferred to our collected data set to further train the classifier. The first data set was collected using pen and paper for the traditional method. The second data set used a tablet and smart pen for data collection. The system’s performance was then evaluated using the data sets.ResultsThe performance of the designed system when using the data set that was collected using the traditional pen and paper method resulted in a mean area under the receiver operating characteristic curve (AUROC) of 0.913 (SD 0.004) when distinguishing between patients with MCI and HCs. On the other hand, when discriminating between patients with AD and HCs, the mean AUROC was 0.950 (SD 0.003) when using the data set that was collected using the digitalized method.ConclusionsThe automatic ROCF test scoring system that we designed showed satisfying results for differentiating between patients with AD and MCI and HCs. Comparatively, our proposed network architecture provided better performance than our previous work, which did not include data augmentation and dropout techniques. In addition, it also performed better than other existing network architectures, such as AlexNet and Sketch-a-Net, with transfer learning techniques. The proposed system can be incorporated with other tests to assist clinicians in the early diagnosis of AD and to reduce the physical and mental burden on patients’ family and friends.

Highlights

  • BackgroundAccording to the latest report from Alzheimer’s Disease International [1], the number of people with dementia worldwide will increase from 50 million in 2019 to 152 million by 2050, and the global annual cost of dementia is estimated to increase from US $1 trillion in 2019 to US $2 trillion in 2030

  • The performance of the designed system when using the data set that was collected using the traditional pen and paper method resulted in a mean area under the receiver operating characteristic curve (AUROC) of 0.913 (SD 0.004) when distinguishing between patients with mild cognitive impairment (MCI) and healthy controls (HCs)

  • As more and more countries’ aging populations increase, there is an urgent need to put more effort into research related to this issue, since there is no cure for Alzheimer disease (AD) and the existing treatment is to extend the period of rapid progression of the disease

Read more

Summary

Introduction

BackgroundAccording to the latest report from Alzheimer’s Disease International [1], the number of people with dementia worldwide will increase from 50 million in 2019 to 152 million by 2050, and the global annual cost of dementia is estimated to increase from US $1 trillion in 2019 to US $2 trillion in 2030. Dementia is the seventh-leading cause of death in the world [2]. These numbers continue to grow year by year, and the risk of developing dementia grows significantly with increasing age. Alzheimer disease (AD) and other types of dementia are considered one of the world’s most pressing health problems for aging people worldwide. It was the seventh-leading cause of death, globally, in 2019. With a growing number of patients with dementia and increasing costs for treatment and care, early detection of the disease at the stage of mild cognitive impairment (MCI) will prevent the rapid progression of dementia. In addition to reducing the physical and psychological stress of patients’ caregivers in the long term, it will improve the everyday quality of life of patients

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call